Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: hyprolose; diacetylated monoglycerides; crospovidone; magnesium stearate; purified talc; hypromellose phthalate; ethylcellulose; light magnesium oxide; mannitol; titanium dioxide; heavy magnesium oxide - indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. ,also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: hyprolose; magnesium stearate; diacetylated monoglycerides; purified talc; ethylcellulose; mannitol; titanium dioxide; light magnesium oxide; carnauba wax; purified water; ethanol absolute; iron oxide red; hypromellose phthalate - ? treatment and prevention of relapse of gastro-oesophageal reflux disease,? symptomatic treatment of gastro-oesophageal reflux disease,? treatment of duodenal ulcers,? treatment of gastric ulcers.,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal antiinflammatory,drugs (nsaids) usually require treatment with antimicrobial agents in addition to,antisecretory drugs whether on first presentation or on recurrence.,it is also indicated, in combination with clarithromycin and amoxycillin, for,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

bafna pharmaceuticals pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: purified talc; titanium dioxide; hyprolose; heavy magnesium oxide; acetylated monoglycerides; ethylcellulose; magnesium stearate; mannitol; hypromellose phthalate; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; hypromellose - rabeprazole alphapharm is indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. ,rabeprazole alphapharm is also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: diacetylated monoglycerides; mannitol; crospovidone; titanium dioxide; ethylcellulose; light magnesium oxide; iron oxide yellow; purified talc; hyprolose; hypromellose phthalate; magnesium stearate; heavy magnesium oxide - indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. ,also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: iron oxide red; hypromellose phthalate; magnesium stearate; diacetylated monoglycerides; magnesium oxide; purified talc; mannitol; titanium dioxide; carnauba wax; ethylcellulose; hyprolose; butan-1-ol; shellac; ethanol absolute; iron oxide black - symptomatic relief of heartburn and other symptoms of gastro-oesophageal reflux disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: diacetylated monoglycerides; hyprolose; magnesium stearate; purified water; light magnesium oxide; iron oxide red; hypromellose phthalate; carnauba wax; ethanol absolute; mannitol; titanium dioxide; purified talc; ethylcellulose - ? treatment and prevention of relapse of gastro-oesophageal reflux disease,? symptomatic treatment of gastro-oesophageal reflux disease,? treatment of duodenal ulcers,? treatment of gastric ulcers.,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal antiinflammatory,drugs (nsaids) usually require treatment with antimicrobial agents in addition to,antisecretory drugs whether on first presentation or on recurrence.,it is also indicated, in combination with clarithromycin and amoxycillin, for,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: ethylcellulose; povidone; titanium dioxide; mannitol; iron oxide red; hypromellose phthalate; sodium starch glycollate type a; light magnesium oxide; magnesium stearate; purified talc; diethyl phthalate - rabeprazole is indicated for: - treatment and prevention of relapse of gastro-oesophageal reflux disease. - symptomatic treatment of gastro-oesophageal reflux disease. - treatment of duodenal ulcers. - treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis. - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: purified talc; iron oxide red; diethyl phthalate; povidone; ethylcellulose; sodium starch glycollate type a; hypromellose phthalate; titanium dioxide; light magnesium oxide; magnesium stearate; mannitol - rabeprazole is indicated for: - treatment and prevention of relapse of gastro-oesophageal reflux disease. - symptomatic treatment of gastro-oesophageal reflux disease. - treatment of duodenal ulcers. - treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis. - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: povidone; mannitol; sodium starch glycollate type a; diethyl phthalate; purified talc; magnesium stearate; hypromellose phthalate; light magnesium oxide; iron oxide red; titanium dioxide; ethylcellulose - rabeprazole is indicated for: - treatment and prevention of relapse of gastro-oesophageal reflux disease. - symptomatic treatment of gastro-oesophageal reflux disease. - treatment of duodenal ulcers. - treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis. - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: mannitol; titanium dioxide; diacetylated monoglycerides; crospovidone; hypromellose phthalate; light magnesium oxide; ethylcellulose; hyprolose; magnesium stearate; purified talc; heavy magnesium oxide - indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. ,also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.